Moderna
MRNA
Performance
About Moderna
Moderna is a biotechnology company focused on developing messenger RNA (mRNA)–based therapeutics and vaccines. It operates globally, including a presence in Germany with Moderna Germany GmbH in Munich, and emphasizes advancing the next generation of transformative medicines through its mRNA platform. The company highlights its mission to address unmet medical needs and bring innovative mRNA-based treatments to patients. The German page features information about the company’s mission, science of mRNA, and contact details for the Munich office.
Recent News
Marty Makary Steps Down as FDA Commissioner After Complaints, Adding to Regulatory Uncertainties
Free Access to BioWorld Coronavirus Articles
FDA Cliffhanger: Will Marty Makary Stay or Go?
Will Pfizer’s Lyme Disease Gamble Pay Off or Set the Space Back?
CDC Confirms Rare Imported Case of Measles From Japan in 7 Years
Healthtech, Biotech: Why the UK Is Emerging as an Essential Hub
The 5 Largest IPOs in Biopharma History
Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In
Pfizer, BioNTech to Pause COVID Vaccine Study Due to Low Enrollment
The UK’s Answer to Darpa Wants to Rewire the Human Brain
Moderna Posts $400M Q1 Revenue, Beats Estimates as Stock Jumps 6.7%
STAT+: Novo Nordisk Strikes Deal with U.S. Startup to Develop Oral Obesity, Diabetes Drugs
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
As RSV Evolves, a Two‑pronged Antibody Cocktail Aims to Stay Ahead
What’s in a Name? Moderna’s “Vaccine” Vs. “Therapy” Dilemma
The FDA’s Proposed “Black Box” Warning for COVID-19 Vaccines
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Stocks Making the Biggest Moves Midday: Moderna, Instacart, Rivian Automotive, DraftKings, Coinbase & More
ShinyHunters Group Targets Over 100 Enterprises, Including Canva, Atlassian, and Epic Games
FDA Backtracks On Moderna mRNA Flu Vaccine Refusal, Sets Aug. 5 Review Deadline
Patents, Defense, and Startups: What Dual-Use Startups Need to Know About Patents in 2026
StockWatch: Trump Order Lifts Psychedelic Drug Shares
OpenAI Debuts GPT-Rosalind, a New Limited Access Model for Life Sciences, and Broader Codex Plugin on Github
Moderna Says FDA Refuses to Review Its Application for Experimental Flu Shot
Rethinking Vaccine Production Platforms for Future Pandemics
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Vaccine Makers Curtail Research and Cut Jobs
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
Jimini Health Secures $17M to Scale Clinician-Supervised Behavioral Health AI
Advances in RSV Vaccine Research and Development
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
OpenAI Launches GPT‑Rosalind, a Life‑sciences LLM for Drug Discovery
Hiring Outlook: February Brings First YOY Job Increase Since 2022
Here’s Where HR and Finance Aren’t in Lockstep, According to Deloitte Data
America Is Losing the Innovation Race
Moderna, After Losing US Funding, Rebounds to Start mRNA Bird Flu Vaccine Trial
Eli Lilly Adds $4.5 B to Indiana Plant Portfolio, Launches First Genetic Medicine Facility
FDA’s Need for Speed Could Strain Small Biotechs. Here’s How They Can Keep Up.
Pfizer Unveils Nanoparticle Platform Aimed at Precision Cancer Therapy
Poland, Romania Ordered to Honor Vaccine Deal with Pfizer
Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
FDA Policy Tracker 2026: Priority Vouchers Questioned, PRVs Return
Marty Makary Set the Conditions for His Own Downfall
Sell in May and Go Away? Why the Old Investing Adage Doesn’t Hold Up in 2026
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline
Being Specific About Being General: Vaccines Edition
FDA Reverses Course on Atara, Pierre Fabre’s Twice-Rejected Cell Therapy After Prasad’s Exit
World AIDS Vaccine Day 2026: What HIV Vaccine Research Is Testing Now